Revance Therapeutics, Inc.
(NASDAQ : RVNC)

( )
RVNC PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
VRXValeant Pharmaceuticals International, Inc.
0.00%18.8814.1%$243.08m
SHPGShire PLC Sponsored ADR
0.00%134.060.4%$206.82m
SAGESAGE Therapeutics, Inc.
0.00%162.379.8%$109.73m
PRGOPerrigo Co. Plc
0.00%89.556.6%$84.14m
ICPTIntercept Pharmaceuticals, Inc.
0.00%61.1222.0%$72.23m
MDCOMedicines Company
0.00%33.1622.1%$61.90m
JAZZJazz Pharmaceuticals Plc
0.00%145.762.2%$57.13m
MNKMallinckrodt Plc
0.00%16.8018.5%$52.82m
UTHRUnited Therapeutics Corporation
0.00%134.9314.5%$52.29m
GWPHGW Pharmaceuticals PLC Sponsored ADR
0.00%131.017.6%$50.60m
CTLTCatalent Inc
0.00%43.382.6%$48.78m
ICLRICON Plc
0.00%115.014.1%$43.90m
CORTCorcept Therapeutics Incorporated.
0.00%15.985.5%$41.19m
PTLAPortola Pharmaceuticals, Inc.
0.00%47.697.8%$39.94m
PBHPrestige Brands Holdings, Inc.
0.00%35.233.8%$39.63m

Company Profile

Revance Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages on the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic, and therapeutic applications. It focuses on the development of daxibotulinumtoxinA, a botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Newark, CA.